The Canadian senate passed Bill C-45 that legalizes recreational marijuana country wide. It passed by a vote of 56-30. Unfortunately, the bill had nearly 4 dozen amendments placed on it, some that allows Provinces to ban personal cultivation(bill says 4 plants per household) as well as stringent restrictions on advertising for Cannabis companies. Because of the amendments, the bill will head back to the House of Commons to approve, reject or modify the amendments. It will then head back to the Senate for another vote.
IIRC, Canada was the first G7 or G20 Nation that legalized medicinal marijuana back in 2001. They are quickly moving towards being the first industrialized nation to legalize recreational marijuana.
https://www.thestar.com/news/canada...to-vote-on-pot-legalization-bill-tonight.html
I say bravo! to our neighbors up North and so does my Roth IRA and brokerage account lol. Im glad that people and their governments are starting to realize the medicinal benefits of Cannabis, as well as recognizing the draconian prohibition laws that have been in place for decades are not working.
Unfortunately for the US, Canadian licensed producers are moving quick and expanding into markets in Europe and Australia for medicinal uses. So from a business standpoint, the longer the US drags its feet on the issue, there will be less market share to capitalize on.
IIRC, Canada was the first G7 or G20 Nation that legalized medicinal marijuana back in 2001. They are quickly moving towards being the first industrialized nation to legalize recreational marijuana.
https://www.thestar.com/news/canada...to-vote-on-pot-legalization-bill-tonight.html
I say bravo! to our neighbors up North and so does my Roth IRA and brokerage account lol. Im glad that people and their governments are starting to realize the medicinal benefits of Cannabis, as well as recognizing the draconian prohibition laws that have been in place for decades are not working.
Unfortunately for the US, Canadian licensed producers are moving quick and expanding into markets in Europe and Australia for medicinal uses. So from a business standpoint, the longer the US drags its feet on the issue, there will be less market share to capitalize on.